Market Place
Sourcing Support
Novartis and Versant Partner to Form Kidney Disease Biotech
23 Aug 2024 //
BIOSPACE
Novartis Completes Acquisition of Chinook Therapeutics
11 Aug 2023 //
GLOBENEWSWIRE
Chinook Announces First Patient Enrolled in Phase 3 BEYOND Study of Zigakibart
28 Jul 2023 //
GLOBENEWSWIRE
Chinook Therapeutics Presents Data from CHK-336 Ph1 Trial in Healthy Volunteers
17 Jun 2023 //
GLOBENEWSWIRE
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
12 Jun 2023 //
GLOBENEWSWIRE
Chinook to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial
12 Jun 2023 //
GLOBENEWSWIRE
Chinook and Ionis partner to develop ASO therapy for kidney disease
17 May 2023 //
PHARMACEUTICAL RECHNOLOGY
Chinook Therapeutics Announces Partnership Ionis to Develop Antisense Therapy
16 May 2023 //
GLOBENEWSWIRE
Chinook shares down about 6%, paring steep loss
16 May 2023 //
REUTERS
Chinook Therapeutics Reports1Q 2023 FYR and Provides Corporate Updates
09 May 2023 //
GLOBENEWSWIRE
Chinook Announces New Employment Inducement Grant Under Nasdaq Listing Rule
06 May 2023 //
BIOSPACE
Chinook Announces Upcoming Presentations Conference Call at the 60th ERA
05 May 2023 //
GLOBENEWSWIRE
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq
05 May 2023 //
GLOBENEWSWIRE
Chinook Therapeutics to Present at Upcoming Investor Conferences
27 Apr 2023 //
GLOBENEWSWIRE
Chinook: CHK-336 Trial Buying Opportunity, Eyes On IgAN Readout
20 Apr 2023 //
SEEKING ALPHA
Chinook Announces the Appointment of Robert W. Azelby to its Board of Directors
13 Apr 2023 //
GLOBENEWSWIRE
Chinook Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Trial
12 Apr 2023 //
GLOBENEWSWIRE
Chinook Therapeutics to Present at Upcoming Investor Conferences
11 Apr 2023 //
GLOBENEWSWIRE
Chinook Announces Employment Inducement Grant Under Nasdaq Rule 5635(c)(4)
07 Apr 2023 //
GLOBENEWSWIRE
Chinook to Present at the Guggenheim Healthcare Talks
28 Mar 2023 //
GLOBENEWSWIRE
Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress
23 Mar 2023 //
GLOBENEWSWIRE
Chinook to Present at the Oppenheimer 33rd Annual Healthcare Conference
07 Mar 2023 //
GLOBENEWSWIRE
Chinook Announces Employment Inducement Grant Under Nasdaq Rule 5635(c)(4)
03 Mar 2023 //
GLOBENEWSWIRE
Chinook Therapeutics Announces Upcoming Presentations at the Summit
28 Feb 2023 //
GLOBENEWSWIRE
Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
27 Feb 2023 //
GLOBENEWSWIRE
Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as CCO
15 Feb 2023 //
MARKETSCREENER
Chinook Announces the Appointment of Andrew Oxtoby as Chief Commercial Officer
15 Feb 2023 //
GLOBENEWSWIRE
Chinook Therapeutics to Present at SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
Chinook Announces New Employment Inducement Grant Under Nasdaq Rule 5635(c)(4)
06 Feb 2023 //
GLOBENEWSWIRE
Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
03 Feb 2023 //
PRESS RELEASE
Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
GLOBENEWSWIRE
Chinook Therapeutics to Present at Upcoming Investor Conferences
22 Nov 2022 //
GLOBENEWSWIRE
Chinook Therapeutics Reports Third Quarter 2022 Financial Results
10 Nov 2022 //
PRESS RELEASE
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial
04 Nov 2022 //
GLOBENEWSWIRE
Chinook Presents Data from Atrasentan Ph2 AFFINITY IgA Nephropathy (IgAN)
03 Nov 2022 //
GLOBENEWSWIRE
Chinook Therapeutics to Present at Upcoming Investor Conferences
02 Nov 2022 //
GLOBENEWSWIRE
Chinook Therapeutics Announces Upcoming Presentations (ASN) Kidney Week 2022
14 Oct 2022 //
GLOBENEWSWIRE
Chinook Therapeutics to Present at Upcoming Investor Conferences
01 Sep 2022 //
GLOBENEWSWIRE
Chinook Therapeutics Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Chinook Receives ODD from EC for BION-1301 in Primary IgA Nephropathy
05 Jul 2022 //
GLOBENEWSWIRE
Chinook Therapeutics to Present at William Blair Biotech Focus Conference 2022
05 Jul 2022 //
GLOBENEWSWIRE
Chinook Therapeutics stock slides on $105M equity offering
25 May 2022 //
SEEKING ALPHA
Chinook Therapeutics Announces Proposed Public Offering
24 May 2022 //
GLOBENEWSWIRE
Chinook Therapeutics Announces Pricing of a $105 Million Public Offering
24 May 2022 //
GLOBENEWSWIRE
Chinook Tx Presents Data from Atrasentan PII AFFINITY IgAN Patient Cohort
20 May 2022 //
GLOBENEWSWIRE
Chinook Therapeutics Stock Gains 8%
19 May 2022 //
RTTNEWS
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial
19 May 2022 //
GLOBENEWSWIRE
Chinook Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Chinook Announces New Employment Inducement Grant
12 May 2022 //
GLOBENEWSWIRE
Chinook Announces Upcoming Data Presentations and Investor Conference Call
02 May 2022 //
GLOBENEWSWIRE
Chinook Therapeutics to Present at the 2022 Bloom Burton &
25 Apr 2022 //
GLOBENEWSWIRE
Chinook Tx Initiates PI Healthy Volunteer Trial of CHK-336 in Hyperoxalurias
12 Apr 2022 //
GLOBENEWSWIRE
Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate
05 Apr 2022 //
GLOBENEWSWIRE
Chinook Tx to Present at the 21st Annual Needham Virtual Healthcare Conference
05 Apr 2022 //
GLOBENEWSWIRE
Chinook Therapeutics Appoints Dr. Mahesh Krishnan to its Board of Directors
21 Mar 2022 //
GLOBENEWSWIRE
Chinook Tx Reports Q4 and FY 2021 Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
Chinook Tx to Present at Oppenheimer`s 32nd Annual Healthcare Conference
08 Mar 2022 //
GLOBENEWSWIRE
Chinook Therapeutics Announces Upcoming Presentations at 4th Annual CKDDD Summit
22 Feb 2022 //
GLOBENEWSWIRE
Chinook Tx Announces Encore Presentations at ISN World Congress of Nephrology`22
18 Feb 2022 //
GLOBENEWSWIRE
Chinook Therapeutics to Present at the 11th Annual SVB Leerink Conference
09 Feb 2022 //
GLOBENEWSWIRE
